News

Clinical Trial for New Lupus Treatment Opens in China

JW Therapeutics has received approval from the National Medical Products Administration of China to conduct a Phase 1 / 2 clinical trial of its CAR T-cell therapy, relmacabtagene autoleucel (relma-cel), for people with moderate to severe and/or treatment-resistant lupus. CAR T-cells are genetically altered T-cells that play a role in the immune response. Scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them to create CAR-T cells.

 

READ FULL ARTICLE

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
News

LUPKYNIS Continues to Show Promising Lupus Nephritis Outcomes

The drug treatment, LUPKYNIS® (voclosporin), reduced inflammation and prevented development of kidney damage in people with lupus nephritis (LN, lupus-related kidney disease) over 18 months. Those taking the medication also didn’t exhibit any signs of kidney-related toxicity. LUPKYINS® is a novel, structurally modified calcineurin inhibitor (CNI) that works in two ways – acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and by promoting podocyte stability in the kidney.

 

READ FULL ARTICLE

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
News

Congratulations to Our Board Members

Congratulations to our board members, Dr. Sam Lim, Georgia State Rep. Kim Schofield and Founder Bryant Reid for being named Community Service awardees at the Phenomenal Women’s Health Annual Fundraising Tea.

 

(Pictured in the photo above l to r: Kim Schofield – Georgia State Representative, Teri Edmond – CEO of Lupus Foundation of America Georgia Chapter, Cheryl Burnside – CEO of Phenomenal Women’s Health, Bryant Reid – President of The Reid Foundation For Lupus, Inc.)

 

READ MORE
News

In People with Lupus, Age and Location Linked to Delayed Follow-Up After Hospitalization

March 30, 2023

Research shows younger people living with lupus and those living in rural or disadvantaged areas are less likely to have a follow-up appointment with their doctor shortly after they’ve been discharged from the hospital. One quarter of people with lupus are hospitalized every year, and one-third are re-hospitalized within 30 days, underscoring the importance of timely outpatient care.

Looking at data from 8,606 adults hospitalized with lupus on Medicare, researchers found that 35% lacked follow-up within 30 days overall. That follow-up rate is worse than the rate reported among people with other chronic diseases.

People with lupus who also exhibited the following characteristics were less likely to have a timely follow-up appointment after hospital discharge:

  • More co-occurring illnesses
  • A longer hospital length-of-stay
  • Rural place of residency
  • Greater neighborhood disadvantage

In the 65 years and older cohort, receiving timely follow-up care was associated with a 65% lower mortality rate in the month following hospital discharge, highlighting the tremendous value of outpatient treatment in this population in particular.

Regular preventative and follow-up care is critically important to living well with lupus, yet many struggle to get the medical support they need. Learn more about barriers to lupus diagnosis and care.

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
  • 1
  • 2